Nearly 97% of transgender and gender-diverse people who began hormone therapy as minors said the treatment was the right decision, according to a new study published Nov. 9 in JAMA Pediatrics. The findings add to a growing body of research examining the long-term experiences of young people who receive gender-affirming care.
The study surveyed former patients of a gender clinic between October 2023 and October 2025. Researchers from the University of Texas Southwestern Medical Center, Boston Children’s Hospital, Lurie Children’s Hospital of Chicago and other institutions examined participants’ experiences with hormone therapy and whether they regretted starting treatment.
Of the 372 participants who completed the Decision Regret Scale, 360 (96.8%) said starting hormone therapy was the right decision. Ten participants (2.7%) reported regret, while seven (1.9%) said they experienced harm from treatment. All seven participants who reported harm also reported regret.
Participants ranged in age from 14 to 28, with an average age of 20.9. Most began hormone therapy at age 17 or younger, with an average starting age of 16. At the time of the survey, 311 participants (82.7%) were still receiving hormone therapy, while 65 (17.3%) had discontinued treatment.
Researchers found higher regret scores among participants who had stopped hormone therapy and those who identified along the nonbinary spectrum. However, the authors cautioned that discontinuing treatment should not automatically be interpreted as regret.
The study did not examine why participants stopped taking hormones, and individuals may discontinue treatment for reasons unrelated to dissatisfaction.
The findings come as states across the country impose restrictions on gender-affirming medical care for minors. Supporters of those restrictions cite concerns about potential harm from treatment and the experiences of people who later discontinue treatment or reverse aspects of their transitions.
The study’s authors argued that their findings support existing medical standards of care and do not justify blanket restrictions on hormone therapy for transgender and gender-diverse youth.
Despite the high rates of satisfaction, researchers acknowledged several limitations that should be considered when interpreting the findings.
Of the 698 former patients invited to participate, 297 did not complete the survey, representing approximately 42.6% of those contacted. Another 25 had never received hormone therapy, leaving 376 participants who had received treatment and completed the survey.
The authors noted that participants assigned male at birth and those who experienced physical gender dysphoria before puberty were less likely to complete the survey. They also acknowledged that recruiting participants through the same clinic where they received treatment could have influenced their responses.
The sample was predominantly White, with 93.6% of participants identifying as White and 19.9% identifying as Hispanic or Latino. Researchers cautioned that the single-clinic sample could limit the generalizability of the findings to other transgender and gender-diverse populations.
The researchers also measured satisfaction with the decision to begin hormone therapy rather than satisfaction with specific physical or psychological effects of treatment. They did not collect information about why participants discontinued treatment.
Channa Jayasena, a professor of reproductive endocrinology at Imperial College London, described the study as well-conducted but raised concerns about potential response bias.
In comments published by the Science Media Centre, Jayasena noted that approximately 40% of those invited to participate did not respond, making it unclear whether their experiences differed from those who completed the survey.
Jayasena also suggested that additional medical-record data could help researchers examine mental health outcomes and adverse events associated with treatment.
To comment please go to one of these social media platforms:
Facebook: https://www.facebook.com/DavisVanguard
LinkedIn: https://www.linkedin.com/company/peoples-vanguard-of-davis-inc/
Instagram: https://www.instagram.com/davisvanguard/
X: https://x.com/davisvanguard
Bluesky: https://bsky.app/profile/vanguardnewsgroup.bsky.social
Subscribe to the Vanguard News letters. To make a tax-deductible donation, please visit davisvanguard.org/donate or give directly through ActBlue. Your support will ensure that the vital work of the Vanguard continues.